| Literature DB >> 33816454 |
Lijuan Sun1, Tongyang Li1, Sen Yu1, Mengmeng Mao1, Dagang Guo1.
Abstract
In recent years, strontium-substituted calcium phosphate bone cement (Sr-CPC) has attracted more and more attentions in the field of bone tissue repair due to its comprehensive advantages of both traditional CPC and Sr ions. In this study, a crucial Sr-containing α-Ca3 - x Sr x (PO4)2 salt has been synthesized using a simplified one-step method at lower synthesis temperature. A novel Sr-CPC has been developed based on the simple binary Sr-containing α-Ca3 - x Sr x (PO4)2/Ca4(PO4)2O cement powder. The physicochemical properties and hydration mechanism of this Sr-CPC at various Sr contents were intensively investigated. The setting product of this Sr-CPC after a set for 72 h is a single-phase Sr-containing hydroxyapatite, and its compressive strength slightly decreased and its setting time extended with the increase of Sr content. The hydration process included the initial formation of the medium product CaHPO4⋅2H2O (30 min∼1 h), the following complete hydration of Ca4(PO4)2O and the initially formed CaHPO4⋅2H2O (2∼6 h), and the final self-setting of α-Ca3 - x Sr x (PO4)2 (6 h∼). The compressive strength of Sr-CPC, which was closely related to the transformation rate of Sr-containing hydroxyapatite, tended to increase with the extension of hydration time. In addition, Sr-CPC possessed favorable cytocompatibility and the effect of Sr ions on cytocompatibility of Sr-CPC was not obvious at low Sr contents. The present study suggests α-Ca3 - x Sr x (PO4)2 is a kind of vital Sr-containing salt source which is useful to develop some novel Sr-containing biomaterials. In addition, the new Sr-containing cement system based on this simple binary α-Ca3 - x Sr x (PO4)2/Ca4(PO4)2O cement powder displayed an attractive clinical application potential in orthopedics.Entities:
Keywords: calcium phosphate bone cement; cytocompatibility; hydration reaction; physicochemical property; strontium
Year: 2021 PMID: 33816454 PMCID: PMC8012852 DOI: 10.3389/fbioe.2021.643557
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Several Sr-CPC bone cements in the present available literatures.
| Name | Composition | Hydration products | Major merits and demerits | Literatures |
| Sr-HAP bone cement | Powder phases: TTCP, DCPA, DSPA Liquid phases: PA | Ca10– | Merits: higher compressive strength, 38.2∼66.5 MPa; | |
| Injectable bioactive bone cement | Powder phases: Sr-HAP, reinforcing silica Liquid phases: D-GMA resin | Sr-HAP, D-GMA resin | Merits: excellent injectability and radiopacity. Demerits: lower compressive strength, 7.15 MPa; lower degradation rate for the resin | |
| Calcium strontium HAP cements | Powder phases: TTCP, α-TCP Liquid phases: Strontium nitrate, orthophosphoric acid | Sr-HAP | Merits: easily prepared. Demerits: high dose of impurity ions (NO3–) contained in the final hardened body. | |
| Sr-containing brushite cement | Powder phases: β-TCP, Ca(H2PO4)2, SrCl2, Na4P2O7 Liquid phases: 2M PA solution | Sr-DCPD, unreacted β-TCP | Merits: excellent cohesion and a diametric tensile strength of 5 MPa. Demerits: some Cl– ions remained in the final hardened body and more than 3 powder phases. | |
| Sr modified biocements | Powder phases: Sr-β-TCP, MCPM Liquid phases: Water | Ca(1–0.25 | Merits: good releasing effect of Sr2+ ions. Demerits: the data about its mechanical properties is not available. | |
| Sr-containing CPC | Powder phases: Sr-ACP, DCPA Liquid phases: deionized water | Sr-HAP, unreacted DCPA | Merits: higher compressive strength, 37∼74.9 MPa; porosity, 55.7∼58.2%. Demerits: the setting time is out of clinical requirement, | |
| Newly developed Sr-substituted α-TCP bone cements | Powder phases: Sr-α-TCP Liquid phases: 10 wt.% poly(ethylene glycol), 20 wt.% citric acid solution; or 0.5 wt.% hydroxyl propyl methylcellulose, 10 wt.% poly(ethylene glycol), 20 wt.% citric acid solution | DCPD, unreacted Sr-α-TCP | Merits: expectable degradability. Demerits: lower compressive strength, 13.7 MPa; complex liquid phase composite. | |
| Ca–Sr-mixed phosphate cement | Powder phases: DCPD, CaO, SC Liquid phases: ammonium phosphate buffer | Sr1.35Ca7.65(HPO4) | Merits: enhanced degradation rate of HAP. Demerits: lower compressive strength, 15.5∼20.1 MPa. | |
| A easy-to-prepare Sr(II)-modified CPC | Powder phases:α-TCP, DCPA, CC, SC, HAP Liquid phases: 4 wt.% Na2HPO4 aqueous solution | HAP, CC, SC, α-TCP, monetite | Merits: higher compressive strength, ∼57.7 MPa. Demerits: complex (5) phases in cement powder; longer setting time, | |
| Sr-incorporated CPC | Powder phases: TTCP, DCPA, DSPA Liquid phases: a combination of citric acid and 12 wt.% polyvinylpyrrolidone K-30 | Apatite | Merits: | |
| Radiopaque brushite cements | Powder phases: MCPM, Na2H2P2O7, β-TCP, SrF2/SrI2/SrBr2/SrCl2⋅6H2O Liquid phases: distilled water | DCPD, β-Ca2P2O7, β-TCP, Monetite, unreacted SrF2 | Merits: increased solubility; higher radiopacity. Demerits: lower wet compressive strength, <8 MPa; lower diametral tensile strength, <4 MPa. Complex phases in cement powder. | |
| CPC | Powder phases: Sr-TTCP, DCPA Liquid phases: phosphate buffer solution, trisodium citrate | HAP, remaining TTCP | Merits: higher compressive strength, 38.66∼60.20 MPa; faster degradation rate; suitable setting time, 10∼17 min. Demerits: the data about its biocompatibility is not available. | |
| Sr-enriched gelatin-CPC | Powder phases: gelatin-α-TCP, DCPD, SrCl2⋅6H2O Liquid phases: distilled water | α-TCP, calcium-deficient HAP | Merits: | |
| Sr-containing CPC | Powder phases: TCP, DSPA, SC, HAP Liquid phases: an aqueous solution of 3 M K2HPO4 and 1.5 M KH2PO4 | HAP | Merits: compressive strength, 34 MPa. Demerits: the data about its setting time is not available. | |
| Sr-substituted α-TCP cements | Powder phases: Sr-α-TCP Liquid phases: 2.5wt.% Na2HPO4 accelerating solution | Sr-HAP, unreacted β-TCP. | Merits: good | |
| Sr-loaded mineral bone cements | Powder phases: DCPD, CC, SC Liquid phases: deionized water or Powder phases: DCPD, CC Liquid phases: SrCl2⋅6H2O solution | CC, carbonated apatite, SC or CC, S-HAP | Merits: enhancing cell proliferation. Demerits: lower porosity. | |
| Sr-doped α-TCP bone cement | Powder phases: Sr-Ca8H2(PO4)6⋅5H2O, α-TCP Liquid phases: 100 mM citric acid solution | HAP | Merits: enhancing degradation and Sr ion release. Demerits: the data about its biocompatibility is not available. | |
| Injectable CPC | Powder phases: ACP, DCPD, SC Liquid phases: deionized water | HAP, SC | Merits: increased injectability and compressive strength, 39.6 MPa. Demerits: the setting time is out of clinical requirement | |
| CPC containing strontium ranelate | Powder phases: partially crystalline calcium phosphate, DCPA, strontium ranelate Liquid phases: deionized water | HAP, DCPA | Merits: good radiopacity and osteogenesis Demerits: the setting time is out of clinical requirement; lower compressive strength, <24 MPa. | |
| Sr-modified premixed CPC | Powder phases: α-TCP, DCPA, SC, HAP, K2HPO4 Liquid phases: liquid consisted of Miglyol 812 with 14.7 wt.% Cremophor ELP and 4.9 wt.% Amphisol A | α-TCP, monetite, HAP, SC | Merits: enhancing mechanical properties; Better radiographic contrast. Demerits: complex powder and liquid phases composite. | |
| A Sr-containing bioactive bone cement | Powder phases: Sr-HAP, fumed silica, benzoyl peroxide Liquid phases: a resin blend (Bisphenol A diglycidylether methacrylate, triethylene glycol dimethacrylate, poly(ethylene glycol) methacrylate, and | Sr-HAP, resin | Merits: setting time, 15∼18 min; compressive strength, 40.9 MPa; bending strength, 31.3 MPa; Bending modulus, 1,408 MPa. Demerits: complex liquid phase composite. | |
| Sr-doped CPC | Powder phases: TTCP, DCPA, SC Liquid phases: ultrapure water | HAP, TTCP, SC | Merits: promoting osteogenic activity. Demerits: the data about its physicochemical properties and | |
| Sr-doped injectable bone cement | Powder phases: Sr-β-TCP, MCPM Liquid phases: water | DCPD, monetite, unreacted β-TCP | Merits: improved injectability; enhanced compressive strength. Demerits: | |
| A novel injectable collagen-Sr-containing CPC | Powder phases: partially crystalline calcium phosphate, DCPA, modified starch Liquid phases: deionized water with type I collagen | HAP | Merits: improved antiwashout property and injectability; higher compressive strength, 21∼48 MPa. Demerits: | |
| Novel injectable Sr-hardystonite phosphate cement | Powder phases: Sr-doped hardystonite, NaH2PO4, Na2B4O7⋅10H2O Liquid phases: deionized water | Sr-doped hardystonite, willemite, silica | Merits: good injectability and handling properties. Demerits: | |
| Sr releasing HAP forming cements | Powder phases: Sr-DCPD, TTCP Liquid phases: DI water or a 1.25% Na2HPO4 solution | Sr-HAP, TTCP | Merits: | |
| Novel Sr containing bioactive glass based CPC | Powder phases: glass (SiO2-P2O5-CaO-SrO-Na2O), Ca(H2PO4)2 Liquid phases: 2.5% Na2HPO4 solution | Sr-HAP | Merits: increasing radiopacity. Demerits: lower compressive strength, <12.5 MPa; longer final setting time. | |
| Sr and hydroxyl ion co-releasing radiopaque HAP cement | Powder phases: Sr-TTCP Liquid phases: 1 M Na2HPO4 and 10 wt.% citric acid | HAP, unreacted TTCP | Merits: | |
| Sr-incorporated biphasic CPC | Powder phases: Sr-β-TCP, TTCP Liquid phases: PA | Sr-β-TCP, Sr-HAP | Merits: suitable operational properties; excellent washout resistance; |
Syntheses of various α-TCP or Sr-α-TCP.
| Sample name | Composition of starting powder | Mean size of the grounded α-TCP particles |
| SC:DCPA:CC | ||
| 0%Sr-α-TCP | 0:2:1 | 7.9 ± 2.3 μm |
| 8.3%Sr-α-TCP | 0.25:2:0.75 | 8.3 ± 1.9 μm |
| 16.7%Sr-α-TCP | 0.50:2:0.50 | 9.5 ± 2.6 μm |
Compositions of various cements and pH values for the SBF after different-sample immersion.
| Sample name | Cement powder | Sr/(Sr+Ca) | pH values for the SBF after different samples immersion | |
| (molar ratio: A:B = 2:1) | ||||
| A | B | |||
| 0Sr-CPC | 0%Sr-α-TCP | TTCP | 0% | 7.430 |
| 5Sr-CPC | 8.3%Sr-α-TCP | TTCP | 5% | 7.433 |
| 10Sr-CPC | 16.7%Sr-α-TCP | TTCP | 10% | 7.537 |
Hydration parameters of various Sr-CPC cements and their effects on the setting time.
| Sample name | L.C. (mol L–1) | P/L ratio | Sr/(Sr+Ca) (×100%) | Setting time (min) | |
| 0Sr-CPC-a | 0.75 | 1.8 | 0% | 1.5 ± 0.2 | 7.0 ± 0.3 |
| 5Sr-CPC-b | 0.75 | 1.8 | 5% | 1.5 ± 0.1 | 7.5 ± 0.5 |
| 10Sr-CPC-c | 0.75 | 1.8 | 10% | 1.5 ± 0.1 | 8.0 ± 0.1 |
| 10Sr-CPC-d | 0.5 | 2.0 | 10% | 2.0 ± 0.2 | 16.0 ± 0.1 |
| 10Sr-CPC-e | 1.0 | 1.6 | 10% | 1.0 ± 0.1 | 4.0 ± 0.4 |
FIGURE 1The XRD patterns of α-TCP containing different Sr contents: (a) α-TCP; (b) 8.3%Sr-α-TCP; and (c) 16.7%Sr-α-TCP.
FIGURE 2The XRD pattern of Ca4(PO4)2O.
FIGURE 3XRD patterns of various Sr-CPC samples after immersed in SBF at 37°C for 72 h: (a) 0Sr-CPC-a; (b) 5Sr-CPC-b; and (c) 10Sr-CPC-c.
FIGURE 4Compressive strength values of Sr-CPC cements with different hydration parameters listed in Table 4 after immersed in SBF at 37°C for 72 h: (a) 0Sr-CPC-a; (b) 5Sr-CPC-b; (c) 10Sr-CPC-c; (d) 10Sr-CPC-d; and (e) 10Sr-CPC-e.
FIGURE 5The SEM morphologies in the typical areas on the fractured surfaces of various Sr-CPC cements after immersed in SBF at 37°C for 72 h: (A,D) 0Sr-CPC-a; (B,E) 5Sr-CPC-b; and (C,F) 10Sr-CPC-c.
EDS data on the surface of the ceramic-like particles in the 10Sr-CPC-c cement after being immersed in SBF at 37°C for 72 h.
| Element | Weight % | Atomic % |
| 41.14 | 63.46 | |
| 18.75 | 14.94 | |
| Ca | 30.83 | 18.99 |
| Sr | 9.28 | 2.61 |
| Total | 100.00 | 100.00 |
FIGURE 6The real-time XRD patterns of the 10Sr-CPC-c samples after immersed in SBF.
FIGURE 7The real-time FESEM photographs of 10Sr-CPC-c samples after hydrating in SBF for different time: (A) 30 min; (B) 1 h; (C) 2 h; (D) 6 h; (E) 10 h; (F) 15 h; (G) 24 h; and (H) 72 h.
FIGURE 8Compressive strength evolution curves of the 10Sr-CPC-c samples immerse in SBF for different hydration stages.
FIGURE 9RGR of MC3T3-E1 cells cultured in different concentrations of extract for (A) 1 day and (B) 3 days.
FIGURE 10Cell number of MC3T3-E1 cells proliferated on the surface of the samples for 1, 4, and 7 days.